文献速递临床试验与 GCP

氯喹对比洛匹那韦/利托那韦治疗轻症/普通型COVID-19疗效研究

Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
PubMed 文献 · Trials · 2020-07-08

本研究为前瞻性、开放标签、多中心、随机对照临床试验,计划纳入轻症/普通型COVID-19感染者,随机分配至磷酸氯喹组或洛匹那韦/利托那韦组,治疗不超过10天,主要结局为完成治疗和随访后28天内的临床恢复时间。背景中提及此前氯喹治疗10例中5例咽拭子核酸转阴,洛匹那韦/利托那韦治疗15例中3例转阴。

要点

  • 比较磷酸氯喹与洛匹那韦/利托那韦对轻症/普通型COVID-19的疗效与安全性。
  • 主要结局为完成治疗和随访后28天内临床恢复时间。
  • 背景数据显示氯喹组咽拭子核酸转阴比例(5/10)高于洛匹那韦/利托那韦组(3/15)。

核心结论

  • 本试验旨在揭示氯喹对比洛匹那韦/利托那韦治疗轻症/普通型COVID-19感染的疗效和安全性。
  • 若含氯喹的新方案显示更高的咽拭子SARS-CoV-2实时荧光RT-PCR转阴率且安全,可作为未来COVID-19治疗进行测试。

研究设计与样本

  • 前瞻性、开放标签、随机对照、多中心临床研究。
  • 研究包括筛选期、治疗期(不超过10天)和随访期。
  • 符合入选条件的COVID-19感染者随机分配至试验组或对照组。
  • 对照组给予洛匹那韦/利托那韦治疗不超过10天,试验组给予磷酸氯喹治疗不超过10天。
  • 主要结局为完成治疗和随访后28天内临床恢复时间。

主要发现

  • 背景中提及洛匹那韦/利托那韦治疗仅帮助少数咽拭子核酸结果改善(3/15)。
  • 背景中提及此前使用氯喹治疗COVID-19患者显示更多咽拭子核酸结果改善(5/10)。

关键数值与推荐

  • 主要结局:完成治疗和随访后28天内临床恢复时间。
  • 次要结局包括完成治疗和随访后治疗成功率、28天内治疗成功时间、严重不良事件发生率、体温恢复正常时间(从发病起计算)。
  • 比较采用双侧检验,统计显著性水平为5%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The outbreak of COVID-19 (caused by SARS-Cov-2) is very serious, and no effective antiviral treatment has yet been confirmed. The adage "old drug, new trick" in this context may suggest the important therapeutic potential of existing drugs. We found that the lopinavir/ritonavir treatment recommended in the fifth edition of the Treatment Plan of China can only help to improve a minority of throat-swab nucleic-acid results (3/15) in hospitals. Our previous use of chloroquine to treat patients with COVID-19 infection showed an improvement in more throat-swab nucleic-acid results (5/10) than the use of lopinavir/ritonavir. METHODS/DESIGN: This is a prospective, open-label, randomized controlled, multicenter clinical study. The study consists of three phases: a screening period, a treatment period of no more than 10 days, and a follow-up period for each participant. Participants with COVID-19 infection who are eligible for selection for the study will be randomly allocated to the trial group or the control group. The control group will be given lopinavir/ritonavir treatment for no more than 10 days. The trial group will be given chloroquine phosphate treatment for no more than 10 days. The primary outcome is the clinical recovery time at no more than 28 days after the completion of therapy and follow-up. The secondary outcomes include the rate of treatment success after the completion of therapy and follow-up, the time of treatment success after no more than 28 days, the rate of serious adverse events during the completion of therapy and follow-up, and the time to return to normal temperature (calculated from the onset of illness) during the completion of therapy and follow-up. Comparisons will be performed using two-sided tests with a statistical significance level of 5%. DISCUSSION: This experiment should reveal the efficacy and safety of using chloroquine versus lopinavir/ritonavir for patients with mild/general COVID-19 infection. If the new treatment including chloroquine shows a higher rate of throat-swab SARS-CoV-2 real-time fluorescent reverse transcription polymerase chain reaction (RT-PCR) negativity and is safe, it could be tested as a future COVID-19 treatment. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR2000029741 . Registered on 11 February 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Liu X, Chen H, Shang Y, et al. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials. 2020. PMID: 32641091. doi:10.1186/s13063-020-04478-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。